Monoclonal antibodies, peptide therapeutics & advanced biologics – made accessible through China's world‑class manufacturing.
Partner Companies
of global APIs
Metric tons annual
Cost reduction
Years legacy
Research articles
China — Sichuan Province · Chengdu · Dayi · Anren Biotech Belt
Connecting the Chengdu · Dayi · Anren Biotech Belt to global markets
Executive-level research platforms powering the Chengdu · Dayi · Anren Biotech Belt
Bacterial, yeast, and mammalian systems
Stable cell line generation
Upstream and downstream optimisation
Comprehensive QC protocols
How Rothschild Corp entered the Chengdu · Dayi · Anren Biotech Belt
In mid-2004, Mr. Yongjun Wen, Chairman of Chengdu Shengnuo Biotec, visited our facility in Panama. Following that visit, he received official green-light approval for cross-border industrial collaboration. This foundational partnership opened Rothschild Corp's entry into China's biotech manufacturing ecosystem.
Today, Chengdu Shengnuo Biotec has grown into a publicly traded company (🟢 688117.SS · Shanghai Stock Exchange) with over 1,600 employees, specializing in peptide API R&D and production.
"Yongjun Wen didn't just build a factory. He built a bridge between two worlds – China's manufacturing excellence and the world's need for affordable, quality biologics."
— Dr. Michael Rothschild, MD, PhD, Founder & CEO
Five pillars — one unified vision
Peptides · Biologics · CDMO
HBrück · Energy Storage
Future Technologies
Healthcare · Education · Climate · Youth
Uniting divisions, building legacy
World-class peptide and biologic production with full regulatory compliance.
Export network via Artemis Bridge™ to 50+ countries.
Full access to the Chengdu · Dayi · Anren Biotech Belt ecosystem.
Long-term partnership built on trust, transparency, and shared vision.